- Home
- VEL vs EBS Comparison
VEL vs EBS Comparison
Compare VEL & EBS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VEL
- EBS
- Stock Information
- Founded
- VEL 2004
- EBS 1998
- Country
- VEL United States
- EBS United States
- Employees
- VEL N/A
- EBS 900
- Industry
- VEL Finance: Consumer Services
- EBS Biotechnology: Pharmaceutical Preparations
- Sector
- VEL Finance
- EBS Health Care
- Exchange
- VEL Nasdaq
- EBS Nasdaq
- Market Cap
- VEL 602.1M
- EBS 529.9M
- IPO Year
- VEL 2020
- EBS 2006
- Fundamental
- Price
- VEL $18.81
- EBS $10.43
- Analyst Decision
- VEL Strong Buy
- EBS Strong Buy
- Analyst Count
- VEL 3
- EBS 2
- Target Price
- VEL $21.67
- EBS $13.50
- AVG Volume (30 Days)
- VEL 59.9K
- EBS 1.4M
- Earning Date
- VEL 11-06-2025
- EBS 10-29-2025
- Dividend Yield
- VEL N/A
- EBS N/A
- EPS Growth
- VEL 26.95
- EBS N/A
- EPS
- VEL 2.22
- EBS 1.35
- Revenue
- VEL $195,592,000.00
- EBS $788,900,000.00
- Revenue This Year
- VEL $3.99
- EBS N/A
- Revenue Next Year
- VEL $29.69
- EBS $15.42
- P/E Ratio
- VEL $8.48
- EBS $7.66
- Revenue Growth
- VEL 44.29
- EBS N/A
- 52 Week Low
- VEL $16.12
- EBS $4.02
- 52 Week High
- VEL $20.98
- EBS $13.41
- Technical
- Relative Strength Index (RSI)
- VEL 60.76
- EBS 54.26
- Support Level
- VEL $17.74
- EBS $9.91
- Resistance Level
- VEL $18.73
- EBS $13.41
- Average True Range (ATR)
- VEL 0.34
- EBS 0.78
- MACD
- VEL 0.06
- EBS 0.00
- Stochastic Oscillator
- VEL 89.17
- EBS 30.33
About VEL Velocity Financial Inc.
Velocity Financial Inc is a United States-based real estate finance company. The company originates and manages investor loans secured by residential rental and small commercial properties. The company earns revenue in the form of interest income. It operates in New York, California, Florida, New Jersey, and other states.
About EBS Emergent Biosolutions Inc.
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. Company operates in three segments namely Commercial Product, MCM Products, and Services segment. The Commercial Product Segment consisting of Nasal Spray; the MCM Products Segment consisting of Anthrax-MCM products, Smallpox-MCM products and Other Products and the Services Segment consisting of Bioservices portfolio. The key revenue is generated through the commercial segment which consists of NARCAN and other commercial products.